Targeted Anticytokine Therapy and the Failing Heart
Open Access
- 6 June 2005
- journal article
- review article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 95 (11), 9-16
- https://doi.org/10.1016/j.amjcard.2005.03.007
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Veterans Affairs (HL-42250-10/10, P50 HL-O6H, RO1 HL58081-01, RO1 HL61543-01)
- National Institutes of Health
This publication has 40 references indexed in Scilit:
- Broad Modulation of Tissue Responses (Immune Activation) by Celacade May Favorably Influence Pathologic Processes Associated with Heart Failure ProgressionThe American Journal of Cardiology, 2005
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Inflammatory Mediators and the Failing HeartCirculation Research, 2002
- Effect of Losartan on Circulating TNF Levels and Left Ventricular Systolic Performance in Patients with Heart FailureEuropean Journal of Preventive Cardiology, 2001
- Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc ReceptorScience, 2001
- Tumor Necrosis Factor (TNF)–α–Induced Interleukin‐8 in Human Blood Cultures Discriminates Neutralization by the p55 and p75 TNF Soluble ReceptorsThe Journal of Infectious Diseases, 2000
- An overview of tumor necrosis factor α and the failing human heartCurrent Opinion in Cardiology, 1999
- Cytokine-binding proteins: stimulating antagonistsImmunology Today, 1995
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureThe New England Journal of Medicine, 1984